Trial Profile

A Phase Ib/II clinical study of HLX701 in combination with cetuximab and chemotherapy for the treatment of patients with advanced RAS/BRAF wild-type colorectal cancer

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 11 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Mar 2026 According to a Henlius Biopharmaceuticals media release, the first patient has been dosed in a Phase 1b/2 trial (HLX701-CRC201) evaluating HLX701, in combination with cetuximab and chemotherapy in patients with advanced RAS/BRAF wild-type metastatic colorectal cancer (mCRC).
19 Mar 2026 According to a Henlius Biopharmaceuticals media release, HLX701 has initiated a phase 2 clinical study in China.
11 Mar 2026 Status changed from planning to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com